- Secondary Narcolepsy
- Narcolepsy with cataplexy
- Narcolepsy without cataplexy
Narcolepsy Treatment Market size was valued at USD 3.2 billion in 2022 and is poised to grow at a CAGR of 9.8% from 2023-2029. Narcolepsy is a lifelong sleeping disorder that makes you feel immensely tired sometimes with uncontrollable sudden sleep attacks in severe cases. It is a disabling condition that is characterized by three different symptoms such as excessive daytime cataplexy, sleepiness, and irresistible sleep episodes, fluctuating automatic behaviors. Narcolepsy generally begins between 15 to 25 years and it can be evident at any age. The narcolepsy treatment market is untreated and undiagnosed in many cases. Narcolepsy is the 3rd most common sleeping disorder which affects a large group of the population. The prevalence rate of narcolepsy is substantially lower in Israel i.e. 1 in 500,000 people and considerably high in Japan i.e. 1 in 600 in comparison with U.S. according to the narcolepsy network. Narcolepsy is not curable but can be treated with drugs like dextroamphetamine, methylphenidate etc. to reduce sleep attacks. Mergers and acquisitions, collaborations, and expansions to untapped geographies are the growth strategies that are adopted by the market players to enhance market growth and to improve their product portfolio. Several voluntary organizations across the world such as Wake up Narcolepsy, Narcolepsy Network, American Sleep Association, and European Narcolepsy Network are actively involved in spreading awareness regarding sleeping disorders and their associated symptoms like EDS, sleep paralysis, and cataplexy.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Factors that are driving the growth of Global Narcolepsy Treatment Market are growing prevalence of various sleeping disorders including narcolepsy, increase awareness about the sleep disorders. Furthermore, increasing demand for advanced diagnostics and therapeutics to treat sleeping disorders and rise in geriatric population. A narcoleptic disorder is proportionately prevalent to Parkinson’s disease, according to the WHO statistics, more than 3 million people are suffering from narcolepsy across the globe. However, stringent regulatory framework, unawareness about the disorder in underdeveloped countries, abuse usage of the drugs, delayed or undiagnosed of the narcolepsy are the few factors which are hampering the growth of narcolepsy treatment market.
The Narcolepsy Treatment Market size was valued at USD 3.2 billion in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The narcolepsy treatment market key players are Arena Pharmaceuticals, Inc.(U.S) BIOPROJET Evotec AG (Germany) Graymark Healthcare, Inc. (U.S) Hypnion, Inc. (U.S) Ligand Pharmaceuticals, Inc.(U.S) Teva Pharmaceutical Industries Ltd.(Israel) Jazz Pharmaceuticals, Inc.,(Ireland)
1. Executive Summary |
2. Global Narcolepsy Treatment Market Introduction |
2.1.Global Narcolepsy Treatment Market - Taxonomy |
2.2.Global Narcolepsy Treatment Market - Definitions |
2.2.1.Type Of Disorder |
2.2.2.Drugs |
2.2.3.Distribution Channel |
2.2.4.Region |
3. Global Narcolepsy Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Narcolepsy Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Narcolepsy Treatment Market By Type Of Disorder, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Secondary Narcolepsy |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Narcolepsy with cataplexy |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Narcolepsy without cataplexy |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Narcolepsy Treatment Market By Drugs, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Amphetamines |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Methylphenidate |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Modafinil |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. MAO-B Inhibitors (Selegiline) |
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Tricyclic Anti-Depressants (TCA) |
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Selective Serotonin Reuptake Inhibitors (SSRI) |
6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Monoamine Oxidase Type-A (MAO-A) inhibitors |
6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
7. Global Narcolepsy Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Hospital pharmacies |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Narcolepsy Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Narcolepsy Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Type Of Disorder Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Secondary Narcolepsy |
9.1.2.Narcolepsy with cataplexy |
9.1.3.Narcolepsy without cataplexy |
9.2. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Amphetamines |
9.2.2.Methylphenidate |
9.2.3.Modafinil |
9.2.4.MAO-B Inhibitors (Selegiline) |
9.2.5.Tricyclic Anti-Depressants (TCA) |
9.2.6.Selective Serotonin Reuptake Inhibitors (SSRI) |
9.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors |
9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Narcolepsy Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Type Of Disorder Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Secondary Narcolepsy |
10.1.2.Narcolepsy with cataplexy |
10.1.3.Narcolepsy without cataplexy |
10.2. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Amphetamines |
10.2.2.Methylphenidate |
10.2.3.Modafinil |
10.2.4.MAO-B Inhibitors (Selegiline) |
10.2.5.Tricyclic Anti-Depressants (TCA) |
10.2.6.Selective Serotonin Reuptake Inhibitors (SSRI) |
10.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors |
10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Narcolepsy Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Type Of Disorder Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Secondary Narcolepsy |
11.1.2.Narcolepsy with cataplexy |
11.1.3.Narcolepsy without cataplexy |
11.2. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Amphetamines |
11.2.2.Methylphenidate |
11.2.3.Modafinil |
11.2.4.MAO-B Inhibitors (Selegiline) |
11.2.5.Tricyclic Anti-Depressants (TCA) |
11.2.6.Selective Serotonin Reuptake Inhibitors (SSRI) |
11.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors |
11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Narcolepsy Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Type Of Disorder Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Secondary Narcolepsy |
12.1.2.Narcolepsy with cataplexy |
12.1.3.Narcolepsy without cataplexy |
12.2. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Amphetamines |
12.2.2.Methylphenidate |
12.2.3.Modafinil |
12.2.4.MAO-B Inhibitors (Selegiline) |
12.2.5.Tricyclic Anti-Depressants (TCA) |
12.2.6.Selective Serotonin Reuptake Inhibitors (SSRI) |
12.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors |
12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Narcolepsy Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Type Of Disorder Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Secondary Narcolepsy |
13.1.2.Narcolepsy with cataplexy |
13.1.3.Narcolepsy without cataplexy |
13.2. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Amphetamines |
13.2.2.Methylphenidate |
13.2.3.Modafinil |
13.2.4.MAO-B Inhibitors (Selegiline) |
13.2.5.Tricyclic Anti-Depressants (TCA) |
13.2.6.Selective Serotonin Reuptake Inhibitors (SSRI) |
13.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors |
13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Arena Pharmaceuticals, Inc.(U.S) |
14.2.2.BIOPROJET |
14.2.3.Evotec AG (Germany) |
14.2.4.Graymark Healthcare, Inc. (U.S) |
14.2.5.Hypnion, Inc. (U.S) |
14.2.6.Ligand Pharmaceuticals, Inc.(U.S) |
14.2.7.Teva Pharmaceutical Industries Ltd.(Israel) |
14.2.8.Jazz Pharmaceuticals, Inc.,(Ireland) |
15. Research Methodology |
16. Appendix and Abbreviations |